Psychiatry organization does not endorse psychedelic treatment
Alcoholism & Drug Abuse Weekly August 5, 2022 DOI: 10.1002/adaw.33520 via Semantic Scholar
Summary
AI-generated from the abstractThe American Psychiatric Association issued a position statement warning about the short- and long-term risks of unapproved psychedelic and empathogenic agents. The statement notes that preliminary research into using these drugs for serious conditions like treatment-resistant depression and post-traumatic stress disorder has generated growing interest in their therapeutic potential.
Study at a glance
| Characteristics | Position statement Peer reviewed |
|---|---|
| Keywords | Psychology |
| Key finding | The APA warns about risks of unapproved psychedelic agents while acknowledging growing interest in their therapeutic potential for serious mental health conditions. |
Abstract
Last month the American Psychiatric Association (APA) issued a position statement on psychedelics warning about the short‐ and long‐term risks of these unapproved drugs. Sanctioned by the APA board of trustees, the “Position Statement on the Use of Psychedelic and Empathogenic Agents for Mental Health Conditions” notes that preliminary research involving psychedelics for the treatment of serious conditions, such as treatment‐resistant depression and post‐traumatic stress disorder, have motivated growing interest in the therapeutic potential of these agents.